Prostate cancer is the most commonly diagnosed cancer in American men
and the second leading cause of cancer death. Approximately 15% of
all men will be diagnosed with prostate cancer during their lifetime.
While the majority of these men have non-aggressive prostate cancer
and die of other causes, it is critically important to identify and
treat aggressive cancers before they escape the prostate.
At Stanford, our doctors are leaders in the use of a new,
image-targeted approach to quickly and accurately diagnose prostate
cancer. Combining ultrasound with a multi-parametric prostate MRI
technique developed at Stanford, targeted
biopsy offers a number of benefits over conventional biopsy methods.
These benefits include:
Sophisticated targeting of cancers that would be missed by
the standard biopsy technique
The ability to access 100% of the prostate, compared to less
than 1% using conventional methods
An improved capacity to distinguish aggressive cancers
requiring treatment from less aggressive cancers that need only
to be monitored
Reduced need for repeat biopsy in the future by reducing the
chance of missing aggressive cancers
After seeing his PSA levels continually increase over several
years, William Armstrong came to Stanford to take an aggressive
approach to diagnosing and treating his prostate cancer.
The doctors of the Stanford
Urologic Cancer Program are dedicated to preserving quality of
life and providing exceptional care directed by customized treatment
plans for each patient.
Advanced treatments and technologies available at Stanford include:
State-of-the-art surgical techniques, including minimally
invasive and robot-assisted surgery
Immunotherapies to leverage the body's immune system to
Image-guided 3D Conformal Radiation Therapy to reduce damage
to important structures surrounding the prostate
Clinical trials of the latest prostate cancer treatments